ARS Pharmaceuticals (SPRY) Fundamental Analysis: Revenue, Earnings & Valuation

1.51 / 10

Underperform

Fundamental rating is Underperform. Core metrics like inventory turnover (3.0) and cost of sales (24.2%) are solid, yet PB‑ROE and Asset‑MV are poor, dragging the overall score to 1.5/10. Prudence recommended.

Analysis Checks(7/10)

Revenue-MV

Value-1.74

Score1/3

Weight35.59%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value-5.46

Score2/3

Weight0.98%

1M Return0.13%

Inventory turnover ratio

Value3.01

Score3/3

Weight-7.04%

1M Return-0.93%

Current liabilities / Total liabilities (%)

Value18.34

Score3/3

Weight13.32%

1M Return1.67%

PB-ROE

Value2.42

Score0/3

Weight24.14%

1M Return2.74%

Long-term debt to working capital ratio (%)

Value0.71

Score3/3

Weight6.27%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-8.31%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value-5.46

Score2/3

Weight0.40%

1M Return0.05%

Cost of sales ratio (%)

Value24.23

Score3/3

Weight2.08%

1M Return0.26%

Asset-MV

Value-0.55

Score0/3

Weight32.57%

1M Return4.00%

Is SPRY fundamentally strong?

SPRY scores 1.51/10 on fundamentals and holds a Premium valuation at present. Backed by its -92.33% ROE, -203.25% net margin, -4.81 P/E ratio, 7.21 P/B ratio, and -2275.00% earnings growth, these metrics solidify its Underperform investment rating.